Healthcare Costs Associated with Adverse Events in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Claims-Based Study
Open Access
- 11 September 2025
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5612-5626
Abstract
Introduction Adverse events (AEs) are common in pediatric patients receiving attention-deficit/hyperactivity disorder (ADHD) treatment; however, real-world studies on their costs from a payer’s perspective are lacking. Therefore, this study investigated the healthcare costs associated with selected AEs among pediatric patients receiving ADHD treatment in the United States. Methods Using a retrospective cohort design, patients aged 6–17 years who received pharmacologic treatment for ADHD were identified from US claims data (October 1, 2015–September 30, 2023) and were categorized into AE and AE-free cohorts, separately for each studied AE. The eight selected AEs had statistically significant risk differences in a matching-adjusted indirect comparison of ADHD treatments and were identifiable from claims with ICD-10-CM codes. Entropy balancing was used to create cohorts with similar characteristics. Total excess healthcare costs and costs associated with AE-specific claims per patient per month (PPPM) were compared across balanced cohorts with vs. without a given AE. Results Overall, 393,919 patients (mean age: 12.5 years; male: 65.4%; stimulant monotherapy: 71.8%) were included, among whom 13.6% had ≥ 1 studied AE that resulted in a medical encounter during their treatment episode. The most prevalent AEs were upper abdominal pain (5.2%), vomiting (3.4%), and insomnia (3.2%). All AEs were associated with substantial AE-specific costs PPPM (asthenia: $196; somnolence: $171; insomnia: $169; vomiting: $106; dizziness: $92; upper abdominal pain: $91; irritability: $75; decreased weight: $46) and total excess healthcare costs PPPM (asthenia: $1178; somnolence: $821; vomiting: $427; insomnia: $404; dizziness: $380; upper abdominal pain: $336; irritability: $231; decreased weight: $219; all p < 0.01). Conclusions AEs were common during ADHD treatment episodes in pediatric patients and were associated with significant healthcare costs. ADHD treatments with a favorable safety profile could help alleviate the economic burden of AEs.Keywords
Funding Information
- Otsuka Pharmaceutical Development & Commercialization, Inc.
This publication has 26 references indexed in Scilit:
- Quality of Life and Outcomes Associated with Adverse Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder and Their Parents/CaregiversJournal of Child and Adolescent Psychopharmacology, 2025
- Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorderJournal of Medical Economics, 2024
- Economic Burden and Service Utilization of Children With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-AnalysisValue in Health, 2023
- Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review StudyAdvances in Therapy, 2022
- Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspectiveJournal of Medical Economics, 2022
- Unique Aspects of Pediatric Sjögren DiseaseRheumatic Disease Clinics of North America, 2021
- Association of Headache With School Functioning Among Children and Adolescents in the United StatesJAMA Pediatrics, 2021
- Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysisNeuroscience & Biobehavioral Reviews, 2021
- Epidemiology of Headache in Children and Adolescents—Another Type of PandemiaCurrent Pain and Headache Reports, 2020
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysisThe Lancet Psychiatry, 2018